Related Experiment Video
Updated: May 25, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Factors influencing progression-free survival in gastrointestinal stromal tumors with special reference to pathologic
Background:
Treatment of gastrointestinal stromal tumors (GISTs) changed significantly with the advent of targeted therapy with imatinib. Clear markers predictive of response to imatinib therapy and disease-free survival in patients with GIST have not been identified. Even RECIST criteria are inadequate for predicting response to therapy, especially in patients with stable disease. Data collected at a tertiary care cancer center from 2003 to 2005 in south India were analyzed retrospectively to assess clinical, pathologic, and cytogenetic profiles of patients with GIST. In addition, radiologic responses to therapy were evaluated for correlation with the disease-free survival.
Methods:
GIST was defined as a mesenchymal spindle/epitheloid cell lesion arising in the GI tract with CD117 positivity. Only data from patients with locally advanced or metastatic disease were analyzed. Clinical and pathologic details of the patients were noted from case records. NCCN guidelines were followed for the treatment. Radiologic response to therapy was reassessed according to RECIST, and progression-free survival calculated for all analyzed patients using intent-to-treat analysis.
Results:
The mean age of presentation was 42.8 ± 5.3 years (24-60), with a male-to-female ratio of 1.5:1. Small intestine was the most common disease site (60%), followed by stomach (20%), mesentery (7.2%), colorectal regions (7.2%), and other sites (5.6%). The most frequent pathologic finding in patients having recurrence was high mitotic rate. Initial tumor size (either in the metastatic setting or in local recurrence) had no bearing on progression-free or overall survival, nor did initial anatomic location or site of metastasis. Histologically, however, patients with a mixed-cell morphology had shorter survival compared to the other morphologies. Those patients having any cytogenetic abnormality had worse outcome compared to those with normal karyotype. Similarly, among patients who achieved remission, those who did so within 12 weeks had better overall survival than did those with a delayed time to remission. Overall survival of patients having stable disease and late partial responses (after 3 months) was similar and superior to survival for patients whose disease progressed while on therapy.
Conclusion:
GISTs characterized by a high mitotic rate and mixed-cell morphology and any cytogenetic abnormalities are associated with poorer outcome. Similarly, shorter time to response was more important than the actual response to therapy. Initial disease site, the site of metastasis, and tumor size had no bearing on outcomes to therapy.
Insights
High mitotic rate, mixed-cell morphology, and cytogenetic abnormalities predict poorer outcomes in gastrointestinal stromal tumors (GISTs). Faster response to imatinib therapy is more crucial than the degree of response for improved survival in GIST patients.
Area of Science:
- Oncology
- Gastroenterology
- Pathology
Background:
- Gastrointestinal stromal tumors (GISTs) treatment advanced with imatinib targeted therapy.
- Predictive markers for imatinib response and disease-free survival in GIST remain elusive.
- RECIST criteria are insufficient for predicting therapy response, especially in stable disease cases.
Purpose of the Study:
- To retrospectively analyze clinical, pathologic, and cytogenetic profiles of GIST patients.
- To evaluate radiologic responses to therapy and their correlation with disease-free survival.
- To identify prognostic factors for GIST patients treated with imatinib.
Main Methods:
- GIST defined as CD117-positive mesenchymal lesions in the GI tract.
- Analysis included patients with locally advanced or metastatic disease.
- Radiologic response assessed by RECIST criteria; progression-free survival calculated via intent-to-treat analysis.
Main Results:
- High mitotic rate and mixed-cell morphology were associated with recurrence.
- Cytogenetic abnormalities correlated with worse outcomes.
- Time to remission within 12 weeks predicted better overall survival compared to delayed response.
Conclusions:
- High mitotic rate, mixed-cell morphology, and cytogenetic abnormalities indicate poorer GIST prognosis.
- Shorter time to therapeutic response is a more significant factor than the extent of response.
- Initial tumor size, disease site, and metastasis site did not impact therapy outcomes.
